Retrospective analysis of clinical characteristics and outcomes of patients with carcinoma of unknown primary from three tertiary centers in Australia
Authors:
Open Access
- 25 March 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (6) , e7052
Abstract
Background: Carcinoma of unknown primary (CUP) remains an important tumor entity and a disproportionate cause of cancer mortality. Little is known about the contemporary clinical characteristics, treatment patterns, and outcomes of CUP patients based on updated international classification guidelines. We evaluated a contemporary CUP cohort to provide insight into current clinical practice and the impact of tissue of origin assignment, site‐specific and empirical therapy in a real‐world setting.Methods: We conducted a retrospective cohort study of CUP patients, as defined by the updated European Society of Medical Oncology (ESMO) 2023 guidelines, across three tertiary referral centers in Australia between 2015 and 2022. We analyzed clinical characteristics, treatment patterns, and survival outcomes using the Kaplan–Meier method and Cox regression proportional hazard model between favorable and unfavorable risk groups.Results: We identified a total of 123 CUP patients (n = 86 unfavorable, n = 37 favorable risk as per the 2023 ESMO guidelines). Sixty‐four patients (52%) were assigned a tissue of origin by the treating clinician. Median progression free survival (PFS) was 6.8 (95% confidence interval (CI) 5.1–12.1) months and overall survival (OS) 10.2 (95% CI 6.0–18.5) months. Unfavorable risk (hazard ratio [HR] 2.9, p = 0.006), poor performance status (HR 2.8, p < 0.001), and non‐squamous histology (HR 2.5, p < 0.05) were associated with poor survival outcome. A total of 70 patients (57%) proceeded to systemic therapy. In patients with non‐squamous histology and unfavorable risk, site‐specific therapy compared to empirical chemotherapy did not improve outcome (median OS 8.2 vs. 11.8 months, p = 0.7).Conclusions: In this real‐world cohort, CUP presentations were heterogenous. Overall survival and rates of systemic treatment were poor. Poor performance status and unfavorable risk were associated with worse survival. For most patients, site‐specific therapy did not improve survival outcome. Improved and timely access to diagnostic tests and therapeutics for this group of patients is urgently required.Keywords
This publication has 31 references indexed in Scilit:
- An audit of cancer of unknown primary notifications: A cautionary tale for population health research using cancer registry dataCancer Epidemiology, 2014
- Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961–2010Cancer Epidemiology, 2014
- Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subsetInternational Journal of Clinical Oncology, 2013
- Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research InstituteJournal of Clinical Oncology, 2013
- A Retrospective Study of Treatment Outcomes in Patients With Carcinoma of Unknown Primary Site and a Colorectal Cancer Molecular ProfileClinical Colorectal Cancer, 2012
- Treatment for Patients With Unknown Primary Cancer and Favorable Prognostic FactorsSeminars in Oncology, 2009
- Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trialBritish Journal of Cancer, 2008
- Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group studyCancer Chemotherapy and Pharmacology, 2007
- Switching benchmarks in cancer of unknown primary: From autopsy to microarrayEuropean Journal of Cancer, 2007
- Cisplatin in Combination With Either Gemcitabine or Irinotecan in Carcinomas of Unknown Primary Site: Results of a Randomized Phase II Study—Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)Journal of Clinical Oncology, 2003